Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 50, Issue 3

Issues

SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians

Vinicius A. Sortica / Marilu Fiegenbaum / Luciana O. Lima / Cézar R. Van der Sand / Luis C. Van der Sand / Maria E.W. Ferreira / Renan C. Pires / Mara H. Hutz

Abstract

Background:Variants in uptake and efflux transporters can influence diverse statin pharmacokinetics in different populations. This study aimed to investigate the influence of SLCO1B1 gene polymorphism on simvastatin treatment efficacy in a Brazilian population of European ancestry.

Methods: Two hundred and sixteen hypercholesterolemic patients were treated with 20 mg/day simvastatin for 6 months. Plasma lipid and lipoprotein levels were measured at baseline and after 2 and 6 months of treatment. The single nucleotide polymorphisms (SNPs) c.388A>G, c.463C>A and c.521T>C at SLCO1B1 gene were determined by allelic discrimination with TaqMan 5'-nuclease assays. The 388G allele was observed in 160 patients, the 521 C allele was observed in 64 individuals, whereas 61 subjects were 463 A allele carriers.

Results: Carriers of the SLCO1B1 388G allele had a greater reduction of total cholesterol and LDL cholesterol with simvastatin treatment, when compared with 56 388A homozygotes (–28.8% vs. –15.8%, p=0.005 and –39.0% vs. –30.6%, p=0.003; respectively). The c.463C>A and c.521T>C SNPs were not associated with simvastatin treatment. The SLCO1B1 haplotypes showed no statistically significant differences in mean percentage reductions in lipid and lipoprotein levels after simvastatin treatment.

Conclusions: The present study suggests that the SLCO1B1 c.388A>G polymorphism could play a role in the inter-individual variation of clinical response to simvastatin in Brazilians. These results add to those that suggest that the effects of SLCO1B1 variants may be statin specific.

Keywords: OATP1B1; SLCO1B1; simvastatin; pharmaco­genetics

About the article

Corresponding author: Professor Mara H. Hutz, Departamento de Genética, Instituto de Biociências, UFRGS, Caixa Postal 15053, 91501-970 Porto Alegre, RS, Brazil Phone: +55 51 3316-6720, Fax: +55 51 3316-7311


Received: 2011-06-20

Accepted: 2011-11-07

Published in Print: 2012-03-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 50, Issue 3, Pages 441–448, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm.2011.804.

Export Citation

©2012 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Vinicius A Sortica, Juliana D Lindenau, Maristela G Cunha, Maria Deise O Ohnishi, Ana Maria R Ventura, Ândrea KC Ribeiro-dos-Santos, Sidney EB Santos, Luciano SP Guimarães, and Mara H Hutz
Pharmacogenomics, 2017
[2]
JP Kitzmiller, JA Luzum, A Dauki, RM Krauss, and MW Medina
Clinical and Translational Science, 2017, Volume 10, Number 3, Page 172
[3]
B Prasad, A Gaedigk, M Vrana, R Gaedigk, JS Leeder, L Salphati, X Chu, G Xiao, CECA Hop, R Evers, L Gan, and JD Unadkat
Clinical Pharmacology & Therapeutics, 2016, Volume 100, Number 4, Page 362
[4]
Yalena Prado, Nicolás Saavedra, Tomás Zambrano, Jenny Lagos, Alexy Rosales, and Luis Salazar
International Journal of Molecular Sciences, 2015, Volume 16, Number 12, Page 20609
[5]
Maarten Leusink, N Charlotte Onland-Moret, Paul IW de Bakker, Anthonius de Boer, and Anke H Maitland-van der Zee
Pharmacogenomics, 2016, Volume 17, Number 2, Page 163
[6]
L Smiderle, M Fiegenbaum, M H Hutz, C R Van Der Sand, L C Van Der Sand, M E W Ferreira, R C Pires, and S Almeida
The Pharmacogenomics Journal, 2016, Volume 16, Number 6, Page 507
[7]
Jasmine A. Luzum, Elizabeth Theusch, Kent D. Taylor, Ann Wang, Wolfgang Sadee, Philip F. Binkley, Ronald M. Krauss, Marisa W. Medina, and Joseph P. Kitzmiller
Journal of Cardiovascular Pharmacology, 2015, Volume 66, Number 1, Page 80
[8]
Ye Dou, Xiaohai Zhu, Qinglu Wang, Xuewen Tian, Jingjing Cheng, and Enying Zhang
Annals of Laboratory Medicine, 2015, Volume 35, Number 3, Page 329
[9]
E. Giannakopoulou, G. Ragia, V. Kolovou, A. Tavridou, A. D. Tselepis, M. Elisaf, G. Kolovou, and V. G. Manolopoulos
Molecular Biology Reports, 2014, Volume 41, Number 7, Page 4631

Comments (0)

Please log in or register to comment.
Log in